cilostazol has been researched along with Arterial Occlusive Diseases in 33 studies
Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Among the key recommendations in this chapter are the following: For patients with chronic limb ischemia, we recommend lifelong aspirin therapy in comparison to no antiplatelet therapy in patients with clinically manifest coronary or cerebrovascular disease (Grade 1A) and in those without clinically manifest coronary or cerebrovascular disease (Grade 1C+)." | 4.82 | Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004) |
| "To evaluate the efficacy of oral administration of cilostazol, an antithrombotic agent, for the prevention of thrombotic occlusion and intimal hyperplasia after stenting." | 3.69 | Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. ( Kichikawa, K; Kimura, Y; Kubota, Y; Maeda, M; Makutani, S; Nishimine, K; Ohishi, H; Sakaguchi, S; Uchida, H; Yoshioka, T, 1995) |
| "Cilostazol is an antiplatelet, antithrombotic agent, which has been used for the treatment of PAOD." | 2.80 | Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. ( Chen, JH; Chuang, TJ; Hsiao, FC; Hsieh, CH; Hung, YJ; Lee, CH; Lin, TK; Liu, JS, 2015) |
| "Cilostazol (200 mg/day) was administered orally for 1 year to 13 patients with 16 lesions (nine symptomatic, seven asymptomatic) confirmed by DSA." | 2.76 | Efficacy of cilostazol for intracranial arterial stenosis evaluated by digital subtraction angiography/magnetic resonance angiography. ( Fujimoto, Y; Yamada, K, 2011) |
| " From a clinical point of view, Cilostazol is indicated in stage IIb of PAOD (Fontaine); its recommended dosage is 2x100 (reduced in case of moderate side effects, 2x50) mg with detectable prolongation of subjective (reported by the patient) and objective walking distance (but not in smokers [!]; ABI-based measurement of the effect not suitable) and partially with an improval of the quality of life (associated with a prolonged but steadily improving therapeutic effect from the 4th to the 6th week until the 6th to the 12th month)." | 2.48 | [Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD)]. ( Halloul, Z; Meyer, F; Weber, M; Weber, T, 2012) |
| "Cilostazol is a phosphodiesterase inhibitor licensed for treating patients suffering from intermittent claudication." | 2.45 | A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. ( Dindyal, S; Kyriakides, C, 2009) |
| "Cilostazol (CLZ) was originally developed as a selective inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3)." | 2.42 | Cilostazol as a unique antithrombotic agent. ( Czerwiec, F; Kambayashi, J; Liu, Y; Shakur, Y; Sun, B; Yoshitake, M, 2003) |
| "Cilostazol was marketed first in Japan in 1988 and later in seven other countries for the treatment of chronic arterial occlusion." | 2.41 | [Research and development of cilostazol: an antiplatelet agent]. ( Kimura, Y; Nakagawa, K; Nishi, T, 2000) |
| "Cilostazol has also been reported to inhibit smooth muscle cell proliferation in vitro and has been demonstrated in a clinical study to favorably alter plasma lipids: to decrease triglyceride and to increase HDL-cholesterol levels." | 2.41 | Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. ( Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M, 2001) |
| "Cilostazol was administered at 200 mg/day for 6 successive weeks to 7 patients (10 lower limbs and 1 upper limb) and at 100 mg/day for 6 weeks to 2 patients (3 lower limbs) and 4 weeks to 1 (1 lower limb), and the skin temperature and skin blood flow were measured in the limbs of these patients." | 1.27 | Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. ( Hyakuna, Y; Iwatani, M; Morioka, Y; Ohashi, S, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.09) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 17 (51.52) | 29.6817 |
| 2010's | 10 (30.30) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kan, CD | 1 |
| Wang, JN | 1 |
| Li, WP | 1 |
| Lin, SH | 1 |
| Chen, WL | 1 |
| Hsu, YP | 1 |
| Yeh, CS | 1 |
| Melzer, J | 1 |
| Saller, R | 1 |
| Warner, CJ | 1 |
| Greaves, SW | 1 |
| Larson, RJ | 1 |
| Stone, DH | 1 |
| Powell, RJ | 1 |
| Walsh, DB | 1 |
| Goodney, PP | 1 |
| Liu, JS | 1 |
| Chuang, TJ | 1 |
| Chen, JH | 1 |
| Lee, CH | 1 |
| Hsieh, CH | 1 |
| Lin, TK | 1 |
| Hsiao, FC | 1 |
| Hung, YJ | 1 |
| Weber, M | 3 |
| Weber, T | 2 |
| Meyer, F | 3 |
| Halloul, Z | 3 |
| Dindyal, S | 2 |
| Sharma, P | 1 |
| Kyriakides, C | 2 |
| Hsieh, CJ | 1 |
| Wang, PW | 1 |
| Soga, Y | 1 |
| Iida, O | 2 |
| Hirano, K | 1 |
| Suzuki, K | 1 |
| Kawasaki, D | 1 |
| Miyashita, Y | 1 |
| Tsuchiya, T | 1 |
| Nobuyoshi, M | 1 |
| Yamada, K | 1 |
| Fujimoto, Y | 1 |
| Graf, D | 1 |
| Panteli, B | 1 |
| Adolf, D | 1 |
| Setacci, C | 1 |
| Castelli, P | 1 |
| Chiesa, R | 1 |
| Grego, F | 1 |
| Simoni, GA | 1 |
| Stella, A | 1 |
| Galzerano, G | 1 |
| Sirignano, P | 1 |
| De Donato, G | 1 |
| Setacci, F | 1 |
| Anand, S | 3 |
| Creager, M | 3 |
| Kambayashi, J | 1 |
| Liu, Y | 2 |
| Sun, B | 1 |
| Shakur, Y | 2 |
| Yoshitake, M | 2 |
| Czerwiec, F | 1 |
| Wilhite, DB | 1 |
| Comerota, AJ | 1 |
| Schmieder, FA | 1 |
| Throm, RC | 1 |
| Gaughan, JP | 1 |
| Rao, AK | 1 |
| Zolli, A | 1 |
| Jelnes, R | 1 |
| Clagett, GP | 1 |
| Sobel, M | 1 |
| Jackson, MR | 1 |
| Lip, GY | 1 |
| Tangelder, M | 1 |
| Verhaeghe, R | 1 |
| Gaddi, AV | 1 |
| Cicero, AF | 1 |
| Regensteiner, JG | 1 |
| Stewart, KJ | 1 |
| Nanto, S | 1 |
| Uematsu, M | 1 |
| Morozumi, T | 1 |
| Kitakaze, M | 1 |
| Nagata, S | 1 |
| Kubota, Y | 1 |
| Kichikawa, K | 1 |
| Uchida, H | 1 |
| Maeda, M | 1 |
| Nishimine, K | 1 |
| Makutani, S | 1 |
| Sakaguchi, S | 2 |
| Yoshioka, T | 1 |
| Ohishi, H | 1 |
| Kimura, Y | 4 |
| Ishizaka, N | 1 |
| Taguchi, J | 1 |
| Ikari, Y | 1 |
| Aizawa, T | 1 |
| Togo, M | 1 |
| Miki, K | 1 |
| Kurokawa, K | 1 |
| Ohno, M | 1 |
| Priollet, P | 1 |
| Carman, TL | 1 |
| Fernandez, BB | 1 |
| Nishi, T | 1 |
| Nakagawa, K | 1 |
| Kambayashi Ji, J | 1 |
| Kawamura, K | 1 |
| Fujita, S | 1 |
| Tani, T | 1 |
| Kamiya, T | 1 |
| Ohashi, S | 1 |
| Iwatani, M | 1 |
| Hyakuna, Y | 1 |
| Morioka, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Predicting Peripheral Arterial Disease in Men With Erectile Dysfunction[NCT00743613] | 175 participants (Actual) | Observational | 2005-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for cilostazol and Arterial Occlusive Diseases
| Article | Year |
|---|---|
[Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review].
Topics: Arterial Occlusive Diseases; Cilostazol; Complementary Therapies; Humans; Intermittent Claudication; | 2013 |
Cilostazol is associated with improved outcomes after peripheral endovascular interventions.
Topics: Arterial Occlusive Diseases; Cilostazol; Endovascular Procedures; Femoral Artery; Global Health; Gra | 2014 |
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
Topics: Angioplasty; Arterial Occlusive Diseases; Cilostazol; Clinical Trials as Topic; Coronary Restenosis; | 2009 |
[Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD)].
Topics: Arterial Occlusive Diseases; Cilostazol; Dose-Response Relationship, Drug; Germany; Humans; Peripher | 2012 |
Restenosis: a challenge for vascular surgeon.
Topics: Animals; Arterial Occlusive Diseases; Cilostazol; Constriction, Pathologic; Humans; Secondary Preven | 2012 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Cilostazol; Combin | 2002 |
Cilostazol as a unique antithrombotic agent.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arterial Occlusive Diseases; Cilostazol; Clinical Tria | 2003 |
Foot ulceration due to arterial insufficiency: role of cilostazol.
Topics: Aged; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Chronic Disease; Cilostazol | 2004 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Cilostazol; Combin | 2002 |
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med | 2004 |
[Treatment of peripheral obstructive artery disease: a battle that could be winned also with drugs?].
Topics: Arterial Occlusive Diseases; Cilostazol; Drug Therapy, Combination; Europe; Glycosaminoglycans; Huma | 2005 |
Established and evolving medical therapies for claudication in patients with peripheral arterial disease.
Topics: Ankle; Arterial Occlusive Diseases; Blood Pressure; Brachial Artery; Cilostazol; Exercise Test; Exer | 2006 |
[Arteriopathy of the lower limbs: toward a global medical care].
Topics: Angiography; Arterial Occlusive Diseases; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Cl | 1999 |
A primary care approach to the patient with claudication.
Topics: Arterial Occlusive Diseases; Cilostazol; Exercise; Humans; Patient Education as Topic; Pentoxifyllin | 2000 |
[Research and development of cilostazol: an antiplatelet agent].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arterial Occlusive Diseases; Cilostazol; Clinical Tria | 2000 |
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Oc | 2001 |
6 trials available for cilostazol and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.
Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Arterial Occlusive Diseases; C-Reactive Protein; Cilo | 2015 |
Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease.
Topics: Adiponectin; Aged; Aged, 80 and over; Ankle; Arterial Occlusive Diseases; Biomarkers; Blood Pressure | 2009 |
Efficacy of cilostazol for intracranial arterial stenosis evaluated by digital subtraction angiography/magnetic resonance angiography.
Topics: Adult; Aged; Angiography, Digital Subtraction; Arterial Occlusive Diseases; Cerebral Arteries; Cilos | 2011 |
[Interims analysis of a prospective observational study on the use of cilostazol (Pletal®) in daily clinical vascularsurgical practice].
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Cilostazol; Exercise Test; Female; Foll | 2011 |
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Cilostazol; Clopidogrel; Drug Therapy, Co | 2003 |
Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Cilostazol; Female; Femoral Artery; Humans; | 2008 |
11 other studies available for cilostazol and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Clinical ultrasound stimulating angiogenesis following drug-release from polymersomes on the ischemic zone for peripheral arterial occlusive disease.
Topics: Angiogenesis Inducing Agents; Animals; Arterial Occlusive Diseases; Bronchodilator Agents; Cilostazo | 2018 |
[Prospective, Systematic Observational Study on the Daily Use of Cilostazol (Pletal) in Clinical Vascular Surgical Practice - Significant Improvement of Walking Distance and Quality of Life for Patients with PAOD, Stage II b].
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Cilostazol; Disability Evaluation; Fema | 2015 |
Regarding "Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions".
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Cilostazol; Constriction, | 2008 |
Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Cilostazol; Female; Femo | 2011 |
[Peripheral arterial occlusive disease (PAVK)].
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteries; Cilostazol; Evidence-Based Medicine; Ex | 2003 |
How reliable is preliminary evidence?
Topics: Arterial Occlusive Diseases; Chronic Disease; Cilostazol; Humans; Platelet Aggregation Inhibitors; R | 2004 |
Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study.
Topics: Administration, Oral; Animals; Arterial Occlusive Diseases; Cilostazol; Dogs; Embolization, Therapeu | 1995 |
Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Angioplasty, Balloon; Animals; Arteria | 1999 |
Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.
Topics: Animals; Arterial Occlusive Diseases; Aspartate Aminotransferases; Azoles; Cilostazol; Creatine Kina | 1985 |
Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities.
Topics: Aged; Ankle; Arterial Occlusive Diseases; Azoles; Chronic Disease; Cilostazol; Fibrinolytic Agents; | 1985 |
Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion.
Topics: Aged; Arterial Occlusive Diseases; Azoles; Cilostazol; Dose-Response Relationship, Drug; Female; Fib | 1985 |